SHS Capital Exits and Reinvests in AMW for Continued Growth

SHS Capital has announced its exit from AMW GmbH, a German specialty pharmaceutical company. Despite the exit, SHS is reinvesting alongside a syndicate of healthcare investors, including Ren Life Sciences and Juno Capital Partners. This move is set to support AMW’s next phase of development, maintaining their long-standing partnership.

AMW, headquartered in Warngau near Munich, specializes in biodegradable, controlled-release drug delivery systems. Since SHS's initial investment, AMW evolved into a profitable company, realizing double-digit growth and substantial EBITDA. The company's products, focusing on prostate cancer treatments, highlight its leadership in biodegradable implants.

The new investment aims to expand existing client relationships, introduce new products, and further internationalize AMW’s operations. The collaboration envisions AMW maintaining its trajectory towards being a global leader in drug delivery solutions.